C4 Therapeutics reported a net margin of -355.90% for the quarter ended Jun 2026. These financial ratios cover 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||||||
| EBT Margin | -290.39% | -77.99% | -413.12% | -194.29% | -473.17% | -1,302.91% | -925.25% | -1,348.42% | -235.13% | -1,057.25% | -933.23% | -147.56% | -160.57% | -665.29% | -363.66% | -402.60% | -286.43% | -184.87% | -408.47% | -355.90% | ||||||||
| EBIT Margin | -285.34% | -75.98% | -409.84% | -197.95% | -481.02% | -1,341.73% | -963.77% | -1,410.21% | -251.16% | -1,147.72% | -1,060.18% | -178.59% | -183.86% | -728.39% | -402.93% | -440.99% | -306.43% | -210.10% | -451.64% | -397.88% | ||||||||
| EBITDA Margin | -285.34% | -75.98% | -409.84% | -197.95% | -481.02% | -1,341.73% | -963.77% | -1,410.21% | -251.16% | -1,147.72% | -1,060.18% | -178.59% | -183.86% | -728.39% | -402.93% | -440.99% | -306.43% | -210.10% | -451.64% | -397.88% | ||||||||
| Operating Margin | -285.34% | -75.98% | -409.84% | -197.95% | -481.02% | -1,341.73% | -963.77% | -1,410.21% | -251.16% | -1,147.72% | -1,060.18% | -178.59% | -183.86% | -728.39% | -402.93% | -440.99% | -306.43% | -210.10% | -451.64% | -397.88% | ||||||||
| Net Margin | -290.39% | -77.99% | -413.12% | -194.29% | -473.17% | -1,302.91% | -925.25% | -1,348.42% | -244.19% | -1,065.75% | -933.23% | -147.56% | -160.57% | -667.82% | -363.66% | -402.60% | -286.43% | -184.87% | -408.47% | -355.90% | ||||||||
| FCF Margin | -215.98% | -128.40% | -349.73% | -182.83% | -425.76% | -1,072.81% | -896.89% | -726.69% | -282.76% | -741.06% | -596.18% | -43.07% | -157.01% | -346.30% | -459.86% | -191.10% | -280.58% | -201.13% | -487.78% | -24.26% | ||||||||
| Efficiency | ||||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 518.17M | 507.34M | 511.12M | 503.98M | 476.96M | 446.14M | 413.44M | 385.52M | 354.01M | 354.73M | 387.41M | 389.73M | 378.58M | 362.83M | 334.56M | 308.03M | 281.01M | 312.28M | 343.97M | 344.13M | ||||||||
| Invested CapitalInvested Cap. | 409.37M | 400.37M | 375.47M | 356.46M | 331.73M | 303.00M | 276.51M | 254.38M | 216.02M | 246.11M | ||||||||||||||||||
| Asset Utilization RatioAsset Util. | 0.07 | 0.09 | 0.09 | 0.10 | 0.10 | 0.07 | 0.07 | 0.04 | 0.06 | 0.06 | 0.05 | 0.08 | 0.09 | 0.10 | 0.12 | 0.11 | 0.11 | 0.12 | 0.10 | 0.10 | ||||||||
| Leverage & Solvency | ||||||||||||||||||||||||||||
| Debt Ratio | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0.06 | ||||||||||||||||||||
| Valuation | ||||||||||||||||||||||||||||
| Price to EarningsP/E | -87.96 | -100.13 | -37.40 | -13.71 | -13.43 | -7.77 | -4.43 | -3.76 | -3.39 | -8.07 | -19.81 | -17.95 | -16.31 | -7.35 | -4.32 | -3.90 | -5.12 | -9.09 | -10.89 | -24.28 | ||||||||
| Price to SalesP/S | 255.43 | 78.08 | 154.52 | 26.64 | 63.56 | 101.23 | 40.97 | 50.65 | 8.28 | 86.01 | 184.90 | 26.48 | 26.18 | 49.11 | 15.69 | 15.71 | 14.66 | 16.80 | 44.48 | 86.43 | ||||||||
| Price to BookP/B | 5.44 | 4.02 | 3.24 | 1.07 | 1.35 | 1.00 | 0.59 | 0.58 | 0.42 | 1.14 | 2.18 | 1.29 | 1.66 | 1.18 | 0.58 | 0.34 | 0.55 | 0.62 | 0.91 | 1.91 | ||||||||
| Enterprise Value | 1,769.08M | 1,258.50M | 891.54M | 60.76M | 115.65M | 12.75M | -116.30M | -132.36M | -124.95M | 26.79M | 303.73M | 53.83M | 146.57M | 9.35M | -101.50M | -113.01M | -27.22M | -63.43M | 37.94M | 320.31M | ||||||||
| EV to EBIT | -72.94 | -82.50 | -28.42 | -2.22 | -3.56 | -0.33 | 3.21 | 3.52 | 4.49 | -0.72 | -9.43 | -2.51 | -5.19 | -0.25 | 3.48 | 3.97 | 0.79 | 2.74 | -1.37 | -12.12 | ||||||||
| EV to EBITDA | -72.94 | -82.50 | -28.42 | -2.22 | -3.56 | -0.33 | 3.21 | 3.52 | 4.49 | -0.72 | -9.43 | -2.51 | -5.19 | -0.25 | 3.48 | 3.97 | 0.79 | 2.74 | -1.37 | -12.12 | ||||||||
| Market Capitalization | 2,171.15M | 1,567.78M | 1,182.71M | 368.54M | 429.30M | 288.90M | 154.02M | 134.93M | 91.62M | 280.47M | 561.92M | 317.93M | 402.21M | 254.25M | 113.58M | 101.54M | 164.67M | 185.11M | 273.62M | 573.97M | ||||||||
| Price to FCFP/FCF | -118.27 | -60.81 | -44.18 | -14.57 | -14.93 | -9.44 | -4.57 | -6.97 | -2.93 | -11.61 | -31.01 | -61.48 | -16.68 | -14.18 | -3.41 | -8.22 | -5.23 | -8.35 | -9.12 | -356.28 | ||||||||
| EV to FCF | -96.37 | -48.82 | -33.31 | -2.40 | -4.02 | -0.42 | 3.45 | 6.84 | 3.99 | -1.11 | -16.76 | -10.41 | -6.08 | -0.52 | 3.05 | 9.15 | 0.86 | 2.86 | -1.26 | -198.82 | ||||||||
| EV to CFO | -96.37 | -49.02 | -33.52 | -2.74 | -4.13 | -0.44 | 3.51 | 6.97 | 4.07 | -1.12 | -16.76 | -10.82 | -6.07 | -0.52 | 3.05 | 9.37 | 0.87 | 2.86 | -1.27 | -203.50 | ||||||||
| Return Ratios | ||||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -285.34% | -75.98% | -409.84% | -197.95% | -481.02% | -1,341.73% | -963.77% | -1,410.21% | -251.16% | -1,147.72% | -1,060.18% | -178.59% | -183.86% | -728.39% | -402.93% | -440.99% | -306.43% | -210.10% | -451.64% | -397.88% | ||||||||
| Return on Capital Employed [ROCE]ROCE | -18.27% | -18.01% | -20.04% | -21.46% | -24.67% | -32.26% | -35.93% | -42.87% | -43.21% | -44.57% | -40.62% | -35.44% | -35.59% | -37.66% | -39.68% | -46.90% | -52.96% | -41.26% | -35.94% | -37.77% | ||||||||
| Return on Invested Capital [ROIC]ROIC | -23.90% | -30.91% | -59.93% | -60.76% | ||||||||||||||||||||||||
| Return on Assets [ROA]ROA | -17.37% | -16.54% | -18.50% | -19.61% | -22.25% | -28.61% | -31.64% | -36.27% | -38.11% | -37.35% | -32.54% | -27.68% | -27.87% | -29.03% | -30.87% | -36.22% | -42.38% | -33.58% | -30.14% | -29.43% |